Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ludovic Samalin

Showing results (31-40 of 122) with videos related to

Pageof 13
Sort By:
Pharmacoeconomics|February 18, 2016
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in FranceSylvain Druais, Agathe Doutriaux, Magali Cognet, et al.
Depression and Anxiety|April 14, 2025
Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French StudyLudovic Samalin, Lila Mekaoui, Maud Rothärmel, et al.
Pharmacoepidemiology and Drug Safety|December 13, 2021
Initiation of quarterly palmitate paliperidone in French clinical practice: Results from the observational, cross-sectional OPTIMUS studyCharlotte Gary, Cécile Déal, Jennifer Boursicot-Beuzelin, et al.
International Journal of Psychiatry in Clinical Practice|September 3, 2024
Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal sprayLudovic Samalin, Lila Mekaoui, Pierre De Maricourt, et al.
Journal of Epidemiology and Population Health|November 3, 2024
From PREMIUM to MyPsy&I®: Transforming mental health care with a digital platform for adaptive PREMs and PROMsLaurent Boyer, Sara Fernandes, Yann Brousse, et al.
Journal of Psychiatric Research|March 14, 2026
Effectiveness and factors associated with esketamine response during the 4-week induction period for treatment-resistant depression: post-hoc analysis of the real-world ESKALE studyLudovic Samalin, Maud Rothärmel, Lila Mekaoui, et al.
L'Encephale|July 3, 2023
[Validated care programs for patients with functional neurological disorders]Gauthier Rauline, Coraline Hingray, Guilhem Carle-Toulemonde, et al.
European Archives of Psychiatry and Clinical Neuroscience|June 18, 2013
A composite scale applied to evaluate anxiety in schizophrenic patients (SAES)Pierre-Michel Llorca, Christophe Lancon, Olivier Blanc, et al.
Archives of Women'S Mental Health|February 17, 2024
French Society for Biological Psychiatry and Neuropsychopharmacology and French-speaking Marcé Society guidelines for the management of mood disorders in women before, during, and after pregnancyRaoul Belzeaux, Florence Gressier, Ludivine Boudieu, et al.
L'Encephale|February 18, 2024
French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024Antoine Yrondi, Hervé Javelot, Bénédicte Nobile, et al.
Pageof 13

Showing results (31-40 of 122) with videos related to

Sort By:
Pageof 13
Pharmacoeconomics|February 18, 2016
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in FranceSylvain Druais, Agathe Doutriaux, Magali Cognet, et al.
Depression and Anxiety|April 14, 2025
Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French StudyLudovic Samalin, Lila Mekaoui, Maud Rothärmel, et al.
Pharmacoepidemiology and Drug Safety|December 13, 2021
Initiation of quarterly palmitate paliperidone in French clinical practice: Results from the observational, cross-sectional OPTIMUS studyCharlotte Gary, Cécile Déal, Jennifer Boursicot-Beuzelin, et al.
International Journal of Psychiatry in Clinical Practice|September 3, 2024
Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal sprayLudovic Samalin, Lila Mekaoui, Pierre De Maricourt, et al.
Journal of Epidemiology and Population Health|November 3, 2024
From PREMIUM to MyPsy&I®: Transforming mental health care with a digital platform for adaptive PREMs and PROMsLaurent Boyer, Sara Fernandes, Yann Brousse, et al.
Journal of Psychiatric Research|March 14, 2026
Effectiveness and factors associated with esketamine response during the 4-week induction period for treatment-resistant depression: post-hoc analysis of the real-world ESKALE studyLudovic Samalin, Maud Rothärmel, Lila Mekaoui, et al.
L'Encephale|July 3, 2023
[Validated care programs for patients with functional neurological disorders]Gauthier Rauline, Coraline Hingray, Guilhem Carle-Toulemonde, et al.
European Archives of Psychiatry and Clinical Neuroscience|June 18, 2013
A composite scale applied to evaluate anxiety in schizophrenic patients (SAES)Pierre-Michel Llorca, Christophe Lancon, Olivier Blanc, et al.
Archives of Women'S Mental Health|February 17, 2024
French Society for Biological Psychiatry and Neuropsychopharmacology and French-speaking Marcé Society guidelines for the management of mood disorders in women before, during, and after pregnancyRaoul Belzeaux, Florence Gressier, Ludivine Boudieu, et al.
L'Encephale|February 18, 2024
French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024Antoine Yrondi, Hervé Javelot, Bénédicte Nobile, et al.
Pageof 13